GAtherton

Latest Aspergillosis & Related Research Updates (Week 4).

Executive overview (what stands out this fortnight)

Key signals

  • Immune dysregulation—not just classic immunosuppression—continues to emerge as a central driver of invasive aspergillosis.

  • Allergic bronchopulmonary aspergillosis (Allergic Bronchopulmonary Aspergillosis) is appearing in atypical and early phenotypes, including absence of bronchiectasis.

  • Antifungal toxicity and pharmacokinetic variability remain clinically important.

  • Paediatric invasive aspergillosis evidence is improving.

  • Environmental and One Health studies continue to inform exposure risk.

  • Overlap with non-tuberculous mycobacteria and microbiome disruption is increasingly evident.

1. Immunocompromise, viral infection, and invasive aspergillosis
Immunocompromise and early-onset invasive pulmonary aspergillosis in viral pneumonia

Sun B et al., Frontiers in Public Health, 2026

Relevance

  • Directly informs understanding of early invasive pulmonary aspergillosis in severe viral pneumonia.
  • Extends COVID-associated pulmonary aspergillosis concepts to non-COVID viral infections.

Key points

  • Viral pneumonia causes early immune dysregulation, including lymphopenia.
  • Invasive aspergillosis may develop before classic intensive care risk factors.
  • Supports earlier fungal surveillance rather than late rescue testing.

Pulmonary cavitation as a late and self-limited complication of COVID-19 pneumonia

Osório M, Silveira M, Cureus, 2026

Relevance

  • Highlights post-viral structural lung damage as a substrate for aspergillosis.

Key points

  • Cavitation discussed alongside COVID-associated pulmonary aspergillosis and mucormycosis.
  • Fungal risk may persist after apparent clinical recovery.

2. Allergic disease and ABPA – expanding phenotypes
Triple autoimmune overlap: rheumatoid arthritis, systemic lupus erythematosus, and hypereosinophilic asthma with ABPA features

Frontiers in Immunology, 2026 (Case Report)

Relevance

  • Challenges rigid diagnostic frameworks for Allergic Bronchopulmonary Aspergillosis.
  • Supports emerging views that ABPA can occur before bronchiectasis develops.

Key points

  • ABPA considered despite normal chest imaging.
  • Diagnosis driven by immunological and eosinophilic markers.

Diagnosis of bronchopulmonary candidiasis—refractory airway hyperresponsiveness and severe pneumonia

Zhang D et al., Frontiers in Medicine, 2026

Relevance

  • Important differential diagnosis for suspected ABPA.

Key points

  • Bronchopulmonary candidiasis can closely mimic ABPA.
  • Normal Aspergillus serology does not exclude other fungal airway disease.

3. Rare immune defects and aspergillosis
Complete and partial forms of X-linked MCTS1 deficiency in patients with mycobacterial disease

Zhou Q et al., Journal of Human Immunity, 2026

Relevance

  • Expands the list of primary immunodeficiencies associated with Aspergillus infection.

Key points

  • Central nervous system aspergillosis identified as a rare but severe phenotype.
  • Suggests impaired cellular immunity as the underlying mechanism.

4. Antifungal therapy – toxicity, variability, and paediatrics
Voriconazole-associated peripheral polyneuropathy: A case report

González BJ et al., Archives of Argentine Pediatrics, 2026
(No PMC full text currently available)

Relevance

  • Highlights clinically important non-hepatic toxicity of azole therapy.

Key points

  • Peripheral neuropathy developed during voriconazole treatment.
  • Symptoms may be insidious and progressive.

RE: Factors affecting voriconazole pharmacokinetic variability in critically ill patients

Langbeen J et al., Critical Care, 2026

Relevance

  • Explains why fixed dosing of voriconazole is often unsafe.

Key points

  • Critical illness alters drug metabolism and clearance.
  • Drug–drug interactions are common.
  • Supports therapeutic drug monitoring and specialist pharmacy input.

Phase 2 clinical trial of posaconazole in paediatric invasive aspergillosis

Kang HJ et al., Antimicrobial Agents and Chemotherapy, 2026
(No PMC full text currently available)

Relevance

  • Rare prospective antifungal data in children.

Key points

  • Posaconazole showed acceptable safety.
  • Clinical responses were encouraging in a high-risk population.

5. Diagnostics, microbiology, and co-infection
Clinical characteristics, molecular diagnosis, and drug resistance profiles of nontuberculous mycobacteria infections

Wang K et al., Clinical and Translational Science, 2026

Relevance

  • Highly relevant to bronchiectasis patients where NTM and aspergillosis frequently coexist.

Key points

  • Molecular diagnostics improve species identification.
  • Resistance patterns complicate treatment strategies.

Impaired systemic antibody response against gut microbiota pathobionts in critical illness

Cho NA et al., Intensive Care Medicine Experimental, 2026

Relevance

  • Links immune–microbiome disruption to susceptibility to Aspergillus fumigatus.

Key points

  • Critical illness impairs antibody responses.
  • Loss of immune balance increases infection risk.

6. Pathogenesis and basic science
Arp2/3 complex contributes to actin-dependent uptake of Aspergillus terreus conidia

Mach N et al., PLOS One, 2026

Relevance

  • Improves understanding of early host–fungus interactions.

Key points

  • Epithelial cells actively internalise Aspergillus conidia.
  • Species differences may influence pathogenicity.

7. Environmental and One Health perspectives
Seasonal variation in Aspergillus abundance in captive penguin burrow sands

Takanobu S et al., Frontiers in Veterinary Science, 2026

Relevance

  • Demonstrates dynamic environmental exposure risk.

Key points

  • Clear seasonal peaks in Aspergillus burden.
  • Correlates with increased disease risk.

Mycotoxins – biomonitoring method including gliotoxin

Berger M et al., MAK Collection for Occupational Health and Safety, 2026

Relevance

  • Gliotoxin explored as a potential biomarker for invasive aspergillosis.

Key points

  • LC-MS/MS methods validated.
  • Currently research-grade rather than clinical.

by GAtherton

Wearable devices and aspergillosis

Are they useful yet – and which ones are the most accurate?

The short answer

Wearable devices do not diagnose aspergillosis and cannot tell what is causing symptoms.
However, some wearables are now good enough to provide useful background information about how your body is coping over time.

Their value lies in:

  • spotting gradual deterioration

  • recognising patterns over weeks or months

  • supporting conversations with your clinical team

They are not a replacement for scans, blood tests, sputum cultures, lung function tests, or specialist review.

What wearables can realistically help with

For people with:

  • Chronic Pulmonary Aspergillosis (CPA)

  • Allergic Bronchopulmonary Aspergillosis (ABPA)

  • Aspergillus bronchitis

  • Aspergillosis with bronchiectasis or asthma

wearables can sometimes help answer:

  • “Am I slowly getting worse, or is this just a bad patch?”

  • “Has my recovery from exertion changed?”

  • “Are my nights becoming more disrupted?”

They are most useful for long-term trends, not day-to-day decisions.

The signals that matter most

From both patient experience and respiratory clinical practice, these signals tend to be most meaningful:

1. Activity tolerance

  • Falling step count over weeks

  • Needing longer to recover after usual activity

  • Avoiding activity you previously managed

➡ Often one of the earliest signs of deterioration.

2. Resting heart rate

  • A persistent rise from your own baseline

  • Especially if not explained by infection, fever, medication or stress

➡ Often reflects physiological strain before symptoms become obvious.

3. Sleep quality

  • Frequent night waking

  • Shortened or fragmented sleep

  • Feeling unrefreshed despite enough hours in bed

➡ Poor sleep often accompanies worsening respiratory symptoms or medication effects.

4. Oxygen saturation (SpO₂) trends

  • Repeated low readings

  • Drops overnight or with exertion

  • Patterns that persist over days or weeks

➡ Trends matter far more than single readings.
➡ Dedicated oxygen monitors are usually more reliable than watches.

What about ECG and breathing rate?

These features are often misunderstood. They are not useless, but they are supportive rather than central in aspergillosis care.

ECG (heart rhythm)

Some wearables can record a single-lead ECG, which may detect:

  • atrial fibrillation

  • sustained rhythm abnormalities

This can be helpful if someone develops:

  • new palpitations

  • breathlessness out of proportion to lung symptoms

  • dizziness or faintness

➡ ECG does not provide information about Aspergillus activity or lung disease progression.

Breathing (respiratory) rate

Most wearables estimate breathing rate indirectly, usually during sleep.

Breathing-rate trends may:

  • support a sense that breathing effort has increased

  • highlight disrupted sleep linked to respiratory load

➡ It cannot distinguish fungal disease from asthma, infection, anxiety or medication effects.

Medication and age matter — a lot

When clinicians interpret wearable data, they always consider:

  • antifungal medicines (e.g. azoles)

  • steroids (current or past)

  • asthma and allergy treatments

  • other long-term conditions

  • age-related physiological change

Common medication effects seen on wearables

  • higher resting heart rate

  • poorer sleep

  • fatigue

  • reduced activity tolerance

These are common and expected and do not automatically mean disease progression.

As we age:

  • recovery slows

  • sleep becomes lighter

  • heart-rate variability reduces

  • oxygen dips more easily overnight

➡ Always compare data to your own baseline, not to “normal” values.

Environment and everyday factors strongly affect readings

Often more than lung disease itself

Wearables measure signals through the skin and movement, not directly from the lungs.

This makes them highly sensitive to environment and daily circumstances.

Many “abnormal” readings reflect conditions around you, not worsening aspergillosis.

Temperature (especially cold)

Cold causes blood vessels in the skin to narrow, which can lead to:

  • falsely low oxygen readings

  • erratic heart-rate data

  • missing or failed measurements

Common situations:

  • cold bedrooms

  • winter walks

  • sleeping with arms outside the duvet

➡ A low oxygen reading in the cold is often technical, not medical.

Altitude and air pressure

At higher altitude (even modest):

  • oxygen saturation normally falls

  • breathing rate may rise

  • sleep may worsen

Examples:

  • flying

  • holidays in hilly or mountainous areas

  • high-rise accommodation

➡ This is normal physiology, not disease progression.

Air quality, humidity and heat

Poor air quality or high humidity can cause:

  • faster breathing

  • increased heart rate

  • worse sleep

  • reduced activity tolerance

➡ Wearables detect body stress, not its cause.

Sleep environment

Sleep data is very sensitive to:

  • noise

  • light

  • room temperature

  • uncomfortable bedding

A poor sleep score often reflects environmental disruption, not lung decline.

Movement, posture and coughing

Night-time data can be affected by:

  • coughing

  • restless sleep

  • sleeping on the arm wearing the device

➡ Night data is often noisy and imperfect.

Hydration, alcohol and meals

  • dehydration → higher heart rate

  • alcohol → worse sleep and altered breathing rate

  • heavy evening meals → raised heart rate

These effects are temporary and not signs of deterioration.

Stress and anxiety

Stress can:

  • raise heart rate

  • increase breathing rate

  • worsen sleep

Wearables cannot distinguish stress from illness, and worrying about readings can make readings worse — a common feedback loop.

What wearables cannot do (important)

  • They cannot diagnose aspergillosis

  • They cannot identify fungal flares

  • They cannot separate cause from effect

  • They cannot replace specialist investigations

They provide context, not answers.

The most accurate consumer devices (2025–26)

Best overall smartwatches

  • Apple Watch (Series 9 / Ultra 2) – excellent heart-rate accuracy, ECG, good sleep trends

  • Withings ScanWatch 2 – health-focused, ECG and oxygen, long battery life

  • Garmin Venu 3 / Epix Pro – excellent activity and recovery tracking

Best non-watch wearables

  • Oura Ring (Gen 3) – strong overnight physiology and sleep trends

  • Wellue O2Ring / similar continuous oximeters – more reliable oxygen trends than watches

These are listed because of better accuracy and consistency, not because they are diagnostic devices.

Can wearable data cause over-worry?

Yes — and this is common, especially in people with long-term lung disease.

Wearables can sometimes:

  • increase anxiety

  • encourage constant checking

  • turn normal variation into worry

  • make people feel unwell even when stable

This is not a personal weakness.

When wearables help

  • checked occasionally

  • viewed over weeks or months

  • used to support (not replace) symptoms

When wearables stop helping

  • if they increase anxiety

  • if they disrupt sleep

  • if numbers override how you feel

➡ It is entirely reasonable to reduce use or stop.

How specialists actually prioritise information

In real aspergillosis care, clinicians still focus on:

  1. How you feel

  2. What you can do

  3. Symptoms and sputum

  4. Imaging and tests

  5. Medication history

Wearable data sits well below these.

The bottom line

  • ✔ Wearables are becoming useful for monitoring trends

  • ✔ ECG and breathing rate add context and safety, not answers

  • ✔ Medication, age and environment strongly affect readings

  • ❌ Wearables do not diagnose aspergillosis

  • ✔ If a device increases anxiety, stepping back is sensible

by GAtherton

How the Body Handles Chemicals, Medicines, and Antifungals

Why metabolism differs between people — and why this matters in aspergillosis

The big idea (in one sentence)

Your body uses an ancient liver detox system to handle chemicals from food, air, and medicines — and differences in that system explain why people with aspergillosis respond so differently to antifungal drugs.

What is metabolism?

Every day, your body is exposed to chemicals from many sources:

  • Food and drink

  • Air pollution and moulds

  • Natural plant chemicals

  • Hormones your body makes itself

  • Medicines, including antifungals and steroids

Many of these chemicals cannot be safely removed in their original form.
They first need to be chemically modified so they can be excreted in urine or bile.

This process is called metabolism, and it happens mainly in the liver.

The liver’s chemical processing system

The liver contains a large family of enzymes called cytochrome P450, often shortened to CYP.

Important clarification

  • CPA = Chronic Pulmonary Aspergillosis (a lung disease)

  • CYP = Cytochrome P450 (liver enzymes)

They sound similar but are completely different things.

What CYP enzymes really do

CYP enzymes did not evolve to deal with medicines.
They evolved to protect us from chemicals in the environment.

They help process:

  • Plant toxins and food chemicals

  • Smoke and air pollution

  • Mould and fungal by-products

  • Alcohol and caffeine

  • Hormones such as cortisol and sex hormones

  • Medicines (which are treated as “foreign chemicals”)

Medicines simply use a system that already existed.

How CYP enzymes “recognise” chemicals

CYP enzymes do not recognise chemicals like the immune system recognises germs.

Instead, they recognise chemical patterns, such as:

  • Fat-solubility (hard to excrete)

  • Size and shape

  • Reactive chemical groups

If a molecule:

  • Fits into the enzyme’s binding pocket, and

  • Can be chemically modified,

then CYP will act on it.

This makes CYP enzymes:

  • Broad (they work on many substances)

  • Flexible

  • Imperfect by design

The two main stages of metabolism (simplified)

Stage 1 – Modification

  • Mainly done by CYP enzymes

  • The chemical is altered (often oxidised)

  • This may:

    • Reduce activity

    • Prepare it for removal

    • Occasionally create a more toxic intermediate

Stage 2 – Packaging for removal

  • The altered chemical is “tagged”

  • It becomes water-soluble

  • It can now leave the body safely

Why metabolism differs between people

This is especially important for aspergillosis patients.

1. Genetics (the biggest factor)

People inherit different versions of CYP enzymes.

Some people:

  • Break drugs down slowly → higher levels → side effects

  • Break drugs down quickly → low levels → reduced effectiveness

Two people on the same antifungal dose can have very different blood levels.

2. Other medicines

Some medicines:

  • Block CYP enzymes (slowing breakdown)

  • Speed up CYP enzymes (lowering drug levels)

Antifungals, steroids, antibiotics, antidepressants, and heart drugs often interact.

3. Inflammation and chronic illness

During infection or chronic inflammation:

  • CYP activity is often reduced

  • Drug levels may rise unexpectedly

This matters in:

  • Chronic Pulmonary Aspergillosis (CPA)

  • Allergic Bronchopulmonary Aspergillosis (ABPA)

  • Bronchiectasis

  • Severe asthma

Drug handling can change during disease flares.

4. Liver health and age

  • Liver disease can slow metabolism

  • Older adults often process drugs differently

Why something can become a “poison”

A substance can cause harm if it:

  • Escapes CYP processing

  • Is metabolised too slowly

  • Overwhelms the system at high dose

  • Blocks CYP so other substances build up

  • Is converted into a toxic by-product

This explains:

  • Why some foods are toxic to dogs but safe for humans

  • Why “natural” substances are not automatically safe

  • Why dose really matters

A key question:

Why not design medicines that CYP can’t break down?

This is a real goal in drug development, and your instinct is correct.

If a drug:

  • Is broken down very slowly, or

  • Avoids CYP metabolism altogether,

then:

  • It stays in the body longer

  • Blood levels are steadier

  • Fewer doses are needed

This is why some medicines are once-daily, once-weekly, or long-acting injections.

But there is a trade-off

CYP metabolism is not just an inconvenience — it is also a safety system.

If a drug:

  • Cannot be metabolised, and

  • Cannot be excreted easily,

then:

  • It may accumulate

  • Side effects last much longer

  • Toxicity is harder to reverse

  • Stopping the drug does not stop the problem quickly

So completely avoiding CYP can increase long-term risk, especially when medicines are taken for months or years.

How drug designers manage this balance

Most modern drugs aim for a middle ground:

  • Broken down slowly, not zero

  • More predictable metabolism

  • Fewer interactions with major CYP enzymes

  • Alternative clearance routes where possible

  • Long-acting formulations (slow release, depots) rather than permanent persistence

In other words:

Long enough to work — but short enough to stay safe

Why this is especially relevant in aspergillosis

Antifungal drugs are particularly challenging because:

  • Fungi are biologically similar to humans

  • Drugs often interact with human CYP enzymes

  • Treatment is long-term

  • Patients often take multiple other medicines

Because of this:

  • Blood level monitoring is common

  • Dose adjustments are expected

  • Side effects do not mean failure

  • Low levels do not mean non-compliance

This variability reflects normal biology, not poor care.

A simple way to think about it

  • Your liver is a chemical processing plant

  • CYP enzymes are general-purpose machines

  • Everyone’s machines run at slightly different speeds

  • Illness and other drugs change how they behave

  • Antifungals depend on these machines being “just right”

Key take-home messages for patients

  • CYP enzymes are part of your body’s everyday detox system

  • They evolved to handle food chemicals, pollution, moulds, and hormones

  • Medicines use the same system

  • People differ because of genetics, illness, and other drugs

  • In aspergillosis, variable drug levels are expected

  • Monitoring and dose adjustment are signs of good specialist care

  • Drugs are not designed to avoid metabolism completely — safety matters as much as convenience

by GAtherton

Antifungal Medicines: Dosing, Monitoring, and the Role of Specialist Care

A detailed reference for patients and non-specialist clinicians

1. Why antifungal treatment is different from most medicines

Oral antifungal medicines—especially azole antifungals—are essential for treating long-term fungal diseases such as chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis.

They differ from many common medicines because they:

  • Have a narrow margin between effectiveness and toxicity

  • Behave very differently between individuals

  • Are often taken for months or years, not days

  • Interact with many commonly prescribed drugs

For these reasons, antifungal treatment requires individualised dosing, monitoring, and specialist input, rather than a standard fixed dose.

2. What “pharmacokinetics” means (plain language)

Pharmacokinetics describes what the body does to a drug:

  1. Absorption – how well the drug enters the bloodstream from the gut

  2. Distribution – how effectively it reaches tissues such as the lungs

  3. Metabolism – how quickly the liver breaks it down

  4. Elimination – how the drug leaves the body

Differences at any of these stages explain why the same dose can be ineffective for one person and toxic for another.

3. Different generations of azole antifungals behave differently

Each generation of azole antifungal was designed to improve effectiveness, but chemical changes also altered how the body handles the drug.

First-generation azoles (older drugs)

Examples

  • Ketoconazole

  • Fluconazole (limited activity against Aspergillus)

Key features

  • Variable absorption

  • Shorter half-life

  • Less reliable lung penetration

Clinical relevance

  • Rarely used now for chronic aspergillosis

Second-generation azoles (mainstay treatment)

Examples

  • Itraconazole

  • Voriconazole

  • Posaconazole

Key features

  • Excellent lung and tissue penetration

  • Highly variable metabolism between people

  • Strong interaction with liver enzymes

Clinical relevance

  • Very effective

  • Blood levels vary widely

  • Dose adjustment and monitoring are often essential

Newer azoles

Example

  • Isavuconazole

Key features

  • More predictable absorption

  • Long, stable half-life

  • Fewer extreme peaks and troughs

Clinical relevance

  • Often better tolerated long-term

  • Monitoring still important, but dosing may be more stable

4. Why the “right dose” matters so much

Too little antifungal

  • Infection not adequately controlled

  • Symptoms persist or worsen

  • Risk of antifungal resistance

  • Fewer future treatment options

Too much antifungal

  • Liver irritation or damage

  • Nausea, appetite loss

  • Neurological or visual side effects

  • Drug accumulation, especially with long-term use

The aim is always the lowest dose that effectively controls the fungus.

https://ars.els-cdn.com/content/image/3-s2.0-B9780123868824000189-f18-07-9780123868824.jpg

5. How clinicians know whether the dose is right

No single test determines this. The correct dose is identified when three elements align:

1️⃣ Blood level testing (therapeutic drug monitoring)

  • Measures how much drug is actually in the bloodstream

  • Helps identify:

    • Under-dosing

    • Target-range dosing

    • Toxic levels

2️⃣ Clinical response

  • Symptoms stabilise or improve

  • Fewer flare-ups or complications

  • Better day-to-day function

3️⃣ Safety monitoring

  • Liver and kidney blood tests

  • Review of side effects

  • Ongoing assessment of drug interactions

Only when effectiveness and safety are both acceptable is the dose considered “right”.

6. Why the right dose can change over time

A dose that was correct initially may later need adjustment because of:

  • Weight or body-composition changes

  • Age-related metabolic changes

  • New medications (including antibiotics or steroids)

  • Changes in liver or kidney function

  • Gradual drug accumulation during long-term therapy

Regular review is therefore expected and appropriate.

7. Is it sometimes impossible to find a stable dose?

Yes. For a minority of patients, a perfectly balanced dose cannot be found.

Reasons include:

  • Extremely fast or slow drug metabolism

  • A very narrow safety window

  • Long-term toxicity despite “acceptable” blood levels

  • Unavoidable interacting medications

  • Liver, kidney, or neurological vulnerability

  • Partial or full antifungal resistance

In these cases, the dose that controls the fungus and the dose that causes side effects may overlap.

This reflects biological limits, not treatment failure.

8. What clinicians do when a stable dose cannot be achieved

Options may include:

  • Switching to a different azole with different pharmacokinetics

  • Using modified dosing schedules (split dosing, slower titration)

  • Accepting a lower suppressive dose rather than full eradication

  • Considering non-azole antifungals where appropriate

  • Prioritising symptom control and quality of life

All are intentional, safety-focused decisions.

9. The central role of the specialist pharmacist

Specialist pharmacists are key to safe antifungal care, particularly for long-term azole therapy.

They play a critical role in:

Interpreting drug levels

  • Assessing whether a level is truly low or high

  • Accounting for dose timing and formulation

  • Preventing unnecessary or unsafe dose changes

Managing drug–drug interactions

Azoles interact with many common medicines, including:

  • Steroids and inhalers

  • Heart rhythm drugs

  • Blood thinners

  • Anti-epileptics

  • Pain medications

The specialist pharmacist:

  • Reviews the full medication list

  • Anticipates interactions before harm occurs

  • Advises on adjusting both interacting drugs

Individualising dosing

When standard doses do not work, they help design:

  • Non-standard doses

  • Split dosing schedules

  • Slow titration plans

  • Alternative azoles with different pharmacokinetics

Protecting patients during long-term treatment

They monitor:

  • Trends in liver and kidney tests

  • Signs of cumulative toxicity

  • Whether symptoms may be drug-related rather than disease-related

Coordinating care

They act as a bridge between:

  • Laboratory results

  • Clinical decision-making

  • Patient experience

https://www.omnicare.com/wp-content/uploads/omnicare-services-overview-02-expert-consultant.jpg

Their involvement often changes management, not just fine-tunes it.

10. Where antifungal drug level testing is done in the UK

In the UK, antifungal drug level testing is centralised.

  • Blood samples are taken locally

  • Samples are sent to specialist reference laboratories, most commonly the
    Mycology Reference Centre Manchester

  • Results are returned to the local clinical team for interpretation

Patients managed through specialist services such as the
National Aspergillosis Centre
benefit from integrated expertise in antifungal pharmacology, imaging, and long-term monitoring.

This process is routine and standard for antifungal care.

11. Key reassurance for patients

  • Dose changes are normal and expected

  • Side effects are often biology-driven, not your fault

  • Blood tests make treatment safer, not riskier

  • Switching drugs is a planned strategy, not giving up

12. One-paragraph summary

Antifungal medicines—particularly azole antifungals—have complex and highly variable behaviour in the body, with a narrow balance between effectiveness and toxicity. Safe use requires individualised dosing, therapeutic drug monitoring, symptom review, and long-term safety checks. Specialist pharmacists play a central role in interpreting drug levels, managing interactions, and tailoring treatment. For some patients, a perfectly balanced dose cannot be achieved, and alternative strategies are required. This reflects biological complexity, not failure, and the overarching aim is always effective fungal control with the best possible long-term safety and quality of life.

by GAtherton

Airways mucus and aspergillosis

A clear, patient-friendly explainer

People living with aspergillosis often say that mucus is one of the hardest symptoms to manage — thick sputum, coughing fits, plugs that feel “stuck”, and flare-ups that seem to come out of nowhere. This explainer brings everything together in one place: what mucus is for, why aspergillosis causes so much of it, why it becomes abnormal, and what current and future treatments aim to do.

1. What is airway mucus and why do we need it?

Mucus is normal, healthy, and essential. Everyone produces it all the time.

Its main roles are to:

  • Trap inhaled particles (dust, spores, bacteria, pollution)

  • Protect the airway lining from drying and irritation

  • Support the immune system

  • Clear the lungs, using tiny moving hairs (cilia) that sweep mucus upwards so it can be swallowed or coughed out
    (this clearance system is called the mucociliary escalator)

In healthy lungs:

  • Mucus is thin

  • Produced in small amounts

  • Cleared without you noticing it

2. Why aspergillosis causes excessive mucus

In aspergillosis, the lungs are under ongoing stress. Several factors combine:

Persistent immune activation

The immune system keeps reacting to Aspergillus material in the airways. Even when the fungus is controlled, inflammation can persist.

Allergic-type inflammation (especially in ABPA)

Allergic immune responses strongly stimulate mucus-producing cells, leading to:

  • Large volumes of mucus

  • Very sticky or rubbery sputum

Airway damage

Conditions commonly associated with aspergillosis (such as bronchiectasis or long-standing asthma) cause:

  • Widened or damaged airways

  • Poor mucus clearance

  • Pools of mucus that are hard to shift

Slowed clearance

Inflammation and infection impair cilia, so mucus:

  • Moves more slowly

  • Sits in the lungs longer

  • Becomes thicker and harder to clear

➡️ What starts as a protective response becomes a self-perpetuating problem.

3. Why thick mucus causes symptoms

Excess or abnormal mucus can:

  • Block airways → breathlessness and wheeze

  • Trigger coughing → especially overnight or on waking

  • Trap infection → repeated flare-ups

  • Reduce oxygen exchange

  • Increase fatigue and chest discomfort

Many patients describe it as:

“Glue-like”, “stringy”, “rubbery”, or “impossible to move”

4. Mucus plugs and crystals – why some mucus is so hard to clear

Mucus plugs

When mucus becomes very thick, it can:

  • Form plugs that partially or completely block airways

  • Show up on CT scans

  • Worsen breathlessness suddenly

Charcot–Leyden crystals

In allergic and eosinophilic airway disease (including allergic bronchopulmonary aspergillosis):

  • Breakdown products of allergic immune cells can form microscopic crystals

  • These crystals make mucus:

    • Stiffer

    • More irritating

    • Harder to clear

Their presence is a sign of ongoing allergic inflammation, not infection alone.

5. Why managing mucus really matters

Mucus is not just an inconvenience. Poor mucus control can:

  • Increase infection risk

  • Drive repeated exacerbations

  • Worsen lung damage over time

  • Reduce quality of life and sleep

  • Increase hospital admissions

For aspergillosis, mucus management is core treatment, not optional.

6. What helps now (current approaches)

A. Thin the mucus

  • Good hydration

  • Nebulised saline (normal or hypertonic)

  • Selected mucolytic medicines (used carefully)

B. Move it out

  • Regular airway clearance physiotherapy

  • Breathing techniques (e.g. active cycle breathing)

  • Oscillating devices (flutter, Acapella, Aerobika)

  • Gentle, regular physical activity where possible

C. Reduce inflammation

  • Inhaled corticosteroids (when appropriate)

  • Oral steroids (used cautiously)

  • Biologic therapies for selected allergic or eosinophilic disease

  • Antifungal treatment when fungal burden is contributing

D. Treat infections early

  • Bacterial infections thicken mucus further

  • Prompt treatment reduces long-term damage

7. What research is doing differently (emerging therapies)

Research is moving beyond simply “loosening mucus”.

1. Reducing mucus production at source

Scientists are developing drugs that aim to:

  • Switch off excessive mucus secretion

  • Preserve normal protective mucus

This targets the mucus-producing cells directly.

2. Blocking the signals that drive over-production

Inflammation sends chemical signals telling airways to make more mucus. New treatments aim to:

  • Calm allergic and immune pathways

  • Prevent expansion of mucus-producing cells

Some current biologic therapies already reduce mucus indirectly; future drugs will be more precise.

3. Changing mucus structure

Instead of thinning everything, researchers are studying ways to:

  • Loosen the internal “mesh” of mucus

  • Prevent dense plugs from forming

  • Restore normal movement by cilia

4. Targeting mucus crystals

In allergic aspergillosis, research is exploring how to:

  • Reduce crystal formation

  • Calm the specific immune responses that create them

5. New inhaled and physical approaches

Early trials are testing:

  • Inhaled therapies designed to mobilise secretions

  • Treatments that improve airflow behind mucus plugs

6. Precision medicine

Future mucus treatments are likely to be:

  • Personalised

  • Based on inflammation type, fungal involvement, airway damage, and immune markers

Two people with aspergillosis may have very different mucus drivers — and need different solutions.

8. What this means for patients today

  • There is no single “anti-mucus cure” yet

  • Promising therapies are in research and early trials

  • Safety and long-term effects must be proven first

For now:

  • Regular airway clearance remains essential

  • Treating inflammation and infection promptly is crucial

  • Understanding why your mucus behaves as it does helps guide treatment

Key messages to remember

  • Mucus is normally protective

  • Aspergillosis turns a helpful system into a problem

  • Thick, sticky mucus reflects ongoing inflammation and airway damage

  • Crystals signal allergic involvement, not just infection

  • Research is moving toward preventing abnormal mucus formation, not just thinning it

by GAtherton

Latest Aspergillosis & Related Research Updates (Week 3).

January–February 2026

Search term is 'aspergillosis'.

This update highlights recent publications relevant to aspergillosis, allergic bronchopulmonary aspergillosis, nontuberculous mycobacterial lung disease, antifungal stewardship, diagnostics, and environmental fungal exposure. Papers are grouped by clinical theme, with key findings and clinical relevance highlighted.

1. Diagnostics, Molecular Methods & Imaging Innovation

Clinical Characteristics, Molecular Diagnosis, and Drug Resistance Profiles of Nontuberculous Mycobacteria Infections

Wang K, Xu D, Gao Y, Zhao W, Ma K
Clinical and Translational Science, 19(2):e70479, Feb 2026

Key highlights

  • Retrospective analysis using polymerase chain reaction melting curve technology to identify nontuberculous mycobacterial species.

  • Demonstrates rapid differentiation of clinically relevant species, with integrated resistance profiling.

  • Highlights marked heterogeneity in clinical presentation and antimicrobial resistance patterns.

Why this matters

  • Increasing relevance for patients with bronchiectasis, chronic obstructive pulmonary disease, and aspergillosis, where nontuberculous mycobacteria co-infection complicates diagnosis and treatment.

  • Supports the shift away from prolonged culture-only pathways toward faster molecular diagnostics.

Amplicon-based sequencing as a diagnostic tool for severe pneumonia in the ICU

Michel C, Imamura H, Yin N, et al.
Scientific Reports, 16(1):2845, Jan 2026

Key highlights

  • Amplicon-based sequencing applied directly to respiratory samples in intensive care.

  • Detects invasive aspergillosis alongside bacterial and viral pathogens.

  • Highlights limitations of current definitions of “proven invasive aspergillosis” when relying solely on histopathology.

Why this matters

  • Reinforces the diagnostic gap in critical care–associated pulmonary aspergillosis.

  • Supports broader adoption of molecular and microbiome-informed diagnostics in high-risk settings.

Deep learning detection and classification of fungal and non-fungal calcifications on paranasal sinus CT imaging

Yang Z, Choi I, Yun H, et al.
PLOS One, 21(1):e0340832, Jan 2026

Key highlights

  • Deep learning model distinguishes fungal ball (commonly aspergillosis) from non-fungal calcifications.

  • High diagnostic accuracy on routine sinus computed tomography scans.

  • Addresses a frequent diagnostic uncertainty in chronic rhinosinusitis.

Why this matters

  • Potential to reduce diagnostic delay and unnecessary surgery.

  • Particularly relevant for centres without ready access to specialist radiology expertise.

2. Invasive Aspergillosis: Expanding Risk Profiles & Clinical Phenotypes

Unmasking Invasive Pulmonary Aspergillosis: Insights From a Case Series at a Tertiary Care Center

Munasinghe K, Nanayakkara A, De Zoysa W, et al.
Cureus, 17(12), Jan 2026

Key highlights

  • Case series illustrating heterogeneous clinical presentations.

  • Emphasises delayed recognition outside classic immunocompromised populations.

  • Reinforces global incidence estimates of approximately 250,000 cases annually.

Why this matters

  • Supports growing recognition that invasive pulmonary aspergillosis occurs in broader patient groups, including those with chronic lung disease and critical illness.

Disseminated Invasive Aspergillosis in a Young Patient With Chronic Alcohol Use and Seemingly Preserved Immunocompetence

Khandwala K, Sawliha Syed H, Anwar S, et al.
Clinical Case Reports, 14(2), Jan 2026

Key highlights

  • Disseminated disease involving multiple organs.

  • Chronic alcohol use identified as a functional immunosuppressive state.

  • Challenges traditional “immunocompetent vs immunocompromised” dichotomy.

Why this matters

  • Reinforces the need for high clinical suspicion even when standard immune markers appear preserved.

  • Relevant for emergency, acute medical, and respiratory teams.

Intensification of Treosulfan–Fludarabine Conditioning With Thiotepa in Allogeneic Hematopoietic Stem Cell Transplantation

Tosoni L, Facchin G, Plos R, et al.
Transplant Direct, 12(2):e1896, Jan 2026

Key highlights

  • Real-world study in older or comorbid transplant recipients.

  • Reports four cases of invasive aspergillosis (three pulmonary, one cerebral).

  • Conditioning regimen was otherwise effective and tolerable.

Why this matters

  • Reinforces persistent invasive fungal infection risk despite modern conditioning approaches.

  • Supports ongoing need for antifungal prophylaxis and surveillance.

Infective Endocarditis Caused by Pan-Azole-Resistant Aspergillus fumigatus in a Lung Transplant Recipient

Ukai K, Kawashima M, Ikeuchi K
Transplant Infectious Disease, Jan 2026

Key highlights

  • Rare but severe manifestation: fungal endocarditis.

  • Pan-azole resistance significantly limited treatment options.

  • Occurred in a lung transplant recipient.

Why this matters

  • Adds to evidence of clinically catastrophic azole resistance.

  • Reinforces importance of resistance testing and antifungal stewardship.

3. Antifungal Toxicity & Stewardship

Voriconazole-associated peripheral polyneuropathy: A case report

González BJ, Ivarola P, Miranda M, et al.
Archivos Argentinos de Pediatría, 124(1), Feb 2026

Key highlights

  • Documents peripheral neuropathy linked to prolonged voriconazole exposure.

  • Emphasises reversibility only after early recognition and drug withdrawal.

Why this matters

  • Highly relevant for patients on long-term antifungal therapy for chronic pulmonary aspergillosis.

  • Supports routine neurological symptom surveillance.

Antifungal Stewardship: Time to Reappraise the Priorities toward Increasing Invasive Fungal Infections

Singh S
Annals of African Medicine, Jan 2026

Key highlights

  • Reviews stewardship challenges across aspergillosis, candidemia, and mucormycosis.

  • Highlights overuse, under-diagnosis, and limited access to diagnostics.

  • Calls for stewardship frameworks equivalent to antibacterial programmes.

Why this matters

  • Directly relevant to azole resistance, drug toxicity, and resource-limited settings.

  • Aligns with national and international fungal disease priorities.

4. Allergy, Mycotoxins & Inflammatory Pathways

Common inflammatory markers predict risk of ABPA development in children with cystic fibrosis

Crabtree HED, Malajczuk CJ, Ho HY, et al.
Journal of Cystic Fibrosis, Jan 2026

Key highlights

  • Identifies routinely measured inflammatory markers predictive of allergic bronchopulmonary aspergillosis.

  • Potential for earlier identification and intervention.

Why this matters

  • May support risk stratification in paediatric cystic fibrosis clinics.

  • Relevant for future screening and monitoring protocols.

Potential mechanisms and effects of AFB1-induced asthma

Yu Z, Gao M, Wu X, et al.
PLOS One, 21(1):e0341172, Jan 2026

Key highlights

  • Network toxicology and molecular docking suggest links between aflatoxin B1 exposure and:

    • Asthma

    • Allergic bronchial pulmonary aspergillosis

    • Lung malignancy in severe cases

Why this matters

  • Strengthens environmental and occupational health links to fungal allergy and chronic lung disease.

  • Supports broader discussion of mould exposure beyond infection alone.

Mycotoxins – Determination of aflatoxins, ochratoxin A, gliotoxin, and others in urine by LC–MS/MS

Berger M, Deharde M, Neuhoff J, et al.
MAK Collection for Occupational Health and Safety, 10(2), Jan 2026

Key highlights

  • Validated biomonitoring method for gliotoxin, aflatoxins, and ochratoxins.

  • Discusses potential use of urine biomarkers for early detection of invasive aspergillosis.

Why this matters

  • Provides methodological groundwork for future biomarker-driven diagnostics.

  • Particularly relevant for occupational and environmental exposure assessment.

Money and Microbes: A Global Systematic Review and Meta-Analysis of Currency Contamination

Appiah PO, Odoom A, Tetteh-Quarcoo PB, Donkor ES
Environmental Health Insights, Jan 2026

Key highlights

  • Identifies paper currency as a reservoir for microbial and fungal contamination.

  • Notes links to serious infections, including pulmonary aspergillosis.

Why this matters

  • Highlights overlooked environmental reservoirs of fungal exposure.

  • Relevant for public health messaging and infection control.

by GAtherton

Surgery for Chronic Pulmonary Aspergillosis (CPA): why it is sometimes considered – and often not

For people living with chronic pulmonary aspergillosis (CPA), the idea of surgery can raise difficult questions. Some patients are told surgery might offer a chance of cure; others are advised very firmly against it. Both positions can be correct, depending on the individual situation.

This article explains when surgery may be considered, why it is often avoided, and what “success” or “cure” really means in CPA.

Why is surgery even considered in CPA

CPA usually develops in lungs that are already damaged (for example, by tuberculosis, chronic obstructive pulmonary disease, bronchiectasis, sarcoidosis, or prior infections). Antifungal medicines are therefore the mainstay of treatment.

However, surgery may be considered in a small and carefully selected group of patients, most commonly when:

1. Disease is localised to one area of the lung

If the aspergillus infection is confined to a single cavity or one lobe, and the rest of the lungs are relatively healthy, it may be technically possible to remove the affected area.

2. Recurrent or life-threatening haemoptysis (coughing up blood)

Large-volume or repeated bleeding is one of the strongest reasons surgery is considered. In some cases, surgery is viewed as a way to prevent catastrophic bleeding, rather than to eradicate infection.

3. A simple aspergilloma

Patients with a simple aspergilloma (a single fungal ball in a cavity, minimal surrounding disease, and preserved lung function) are the group most likely to benefit.

4. Failure or intolerance of antifungal therapy

If antifungal drugs cannot be taken long term due to side effects, drug resistance, or lack of response—and the disease remains localised—surgery may be discussed.

Why surgery is often not recommended

Although surgery can sound appealing, CPA surgery is high-risk and not suitable for most patients.

1. CPA is often widespread

Many patients have a disease affecting both lungs or multiple lobes. Removing one area does not treat the remaining infection.

2. Underlying lung reserve is limited

CPA commonly occurs in people with reduced lung function. Removing lung tissue can lead to:

  • Long-term breathlessness

  • Oxygen dependence

  • Reduced quality of life

Even if the operation itself is technically successful.

3. Surgery carries significant risks

Compared with many other lung operations, CPA surgery has higher complication rates, including:

  • Prolonged air leaks

  • Serious infections

  • Bleeding

  • Bronchopleural fistula (abnormal airway–pleural connection)

  • Need for prolonged hospitalisation or intensive care

4. Surgery does not address the underlying vulnerability

CPA reflects an ongoing susceptibility of the lung environment. Removing one fungal focus does not remove the underlying reason aspergillus was able to grow in the first place.

What is the “success rate” of surgery?

Success depends heavily on patient selection and surgical expertise.

In specialist centres:

  • Operative mortality (risk of death around the time of surgery):
    Typically reported between 1–5%, but higher in complex diseases.

  • Major complication rates:
    Often 15–40%, depending on disease extent and lung health.

  • Symptom improvement:
    Many patients selected for surgery experience reduced haemoptysis and improved local control of disease.

These figures are why surgery is only offered after careful multidisciplinary discussion, usually involving respiratory physicians, infectious disease specialists, thoracic surgeons, and radiologists.

Is surgery a “cure” for CPA?

This is one of the most misunderstood points.

Short answer: sometimes, but often not in the long term

  • In a simple aspergilloma, surgery can be genuinely curative if:

    • The disease is completely removed

    • There is no other active CPA elsewhere

    • The patient’s lungs remain stable

  • In chronic cavitary or fibrosing CPA, surgery is rarely a true cure. Instead, it may:

    • Control bleeding

    • Remove a particularly problematic area

    • Reduce fungal burden

Even after apparently successful surgery, some patients still require:

  • Long-term antifungal therapy

  • Ongoing monitoring with scans and blood tests

Recurrence of aspergillus infection elsewhere in the lungs can occur months or years later.

Why are many patients managed medically instead

For most people with CPA, long-term antifungal therapy offers:

  • Disease stabilisation

  • Symptom control

  • Lower risk than surgery

While antifungals do not usually “cure” CPA either, they can:

  • Slow or halt progression

  • Reduce inflammation and symptoms

  • Improve quality of life

This is why surgery is best seen as a highly selective tool, not a standard treatment.

How decisions about surgery are made

If surgery is discussed, your team will usually consider:

  • Extent and pattern of CPA on imaging

  • Lung function tests

  • General fitness and other medical conditions

  • History of haemoptysis

  • Response and tolerance to antifungal treatment

  • Your own priorities and acceptable trade-offs

Importantly, being told surgery is not advised does not mean your care is being limited—it usually reflects a judgement that risks outweigh benefits in your specific case.

Key messages for patients

  • Surgery for CPA is uncommon and highly selective

  • It is most useful in localised disease or severe bleeding

  • Complication rates are significant

  • A guaranteed or permanent “cure” is not typical, except in carefully chosen cases

  • Long-term medical management remains the safest and most effective option for most patients

If surgery has been mentioned—or ruled out—in your case, it is reasonable to ask your team:

  • What specific problem would surgery aim to solve for me?

  • What risks apply to my lungs and overall health?

  • Would antifungal treatment still be needed afterwards?

These discussions are an important part of shared decision-making in CPA care.

by GAtherton

Connecting patients, carers, clinicians and scientists to improve life with aspergillosis

World Aspergillosis Day (WAD) is an annual global event that brings together people who live with, care for, treat, and research long-term forms of aspergillosis — particularly chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA).

Each year, WAD creates a shared space where:

  • patients and carers can hear directly from specialists,

  • clinicians and scientists can learn from patient experience,

  • and everyone can explore how new research translates into better care.

🎥 Missed previous events?
Recordings from earlier World Aspergillosis Day meetings are available on our YouTube channel.

📅 NAC World Aspergillosis Day Meeting 2026

The National Aspergillosis Centre (NAC) will once again host a free online meeting:

🗓 Tuesday 3 February 2026
💻 Online via Microsoft Teams
👥 Open to patients, carers, clinicians, scientists, and anyone who lives or works with aspergillosis

🧬 This year’s theme:

“How can the genomics revolution help patients with chronic aspergillosis?”

Why genomics — and why now?

Modern molecular tests such as PCR and DNA sequencing are becoming faster, cheaper and more accurate. Because of this, the NHS is increasingly exploring how genomic technologies can be used to improve diagnosis, monitoring and treatment across many diseases — including aspergillosis.

This year’s WAD meeting will start an open discussion between patients and professionals about which genomic and molecular tests are likely to matter most for people with aspergillosis in the years ahead.

Topics will include:

  • 🧠 Is there a “gene for aspergillosis”?
    Should people be tested for genetic susceptibility?

  • 💊 Genes and voriconazole dosing
    Can testing the CYP2C19 gene help personalise antifungal treatment?

  • 🦠 Tracking antifungal resistance
    How molecular testing of Aspergillus strains can help hospitals monitor resistance.

  • 🔬 Aspergillus PCR at NAC
    How PCR is already used to diagnose and monitor chronic aspergillosis.

🗣️ Patient voices at the heart of the meeting

As always, patient experience will be central to the day.

This year will include new patient stories, including Alison, who will talk about how her aspergillosis treatment led to the development of adrenal insufficiency, and what that has meant for her care and daily life.

“I don’t know anything about genetics — is this for me?”

Absolutely yes.

You don’t need any background in genetics to take part. Everything will be explained clearly, step by step, with minimal jargon.

Planned discussion topics include:

  • What do my Aspergillus PCR test results actually mean?

  • Is there really a “gene for CPA”?

  • Why do genes matter for antifungal dosing?

In fact, the more questions you ask — especially the “silly” ones — the better. The discussion from the day will be used to create a new patient leaflet, designed to help people better understand their diagnosis and test results.

✅ Registration is now open

🎟 Book your free place via Eventbrite:
👉 www.eventbrite.co.uk/e/world-aspergillosis-day-tickets-1980707139373

💻 Joining via Microsoft Teams

The meeting will be held online using Microsoft Teams, which you can download here:
👉 www.microsoft.com/en-gb/microsoft-teams/group-chat-software

If you haven’t used Teams before, we recommend doing a test call in advance. If you run into any problems setting things up, we’re very happy to help.

We hope you can join us for World Aspergillosis Day 2026 — to learn, to ask questions, and to help shape the future of aspergillosis care together.

by GAtherton

When discharge from a specialist service is being discussed

A reassuring explanation for people with long-standing Aspergillus bronchitis

This page is for people who have lived for many years with a diagnosis of Aspergillus bronchitis, and who are now hearing that discharge from a specialist or tertiary service may be discussed, or is being gently considered.

Many patients tell us this brings up worries such as:

  • “Does this mean I’m less safe?”

  • “Does this mean they’re not sure anymore?”

  • “What if things get worse later?”

These feelings are very common, and they make sense.

First — nothing has been decided yet

If discharge is being discussed, it usually means:

  • Your team is reviewing your care carefully

  • They are looking at whether regular specialist follow-up is still helping right now

  • They are not withdrawing care, and not closing doors

Discussion is part of good medicine — especially with conditions that can change slowly over time.

Why might discharge even come up after many years?

This can feel surprising, but it is usually because:

  • Your condition has been stable for a long time

  • There has been no clear progression

  • Specialist treatments are not currently being changed

  • Ongoing follow-up may not be adding extra benefit at this stage

This is often a sign of relative stability, not doubt or disbelief.

Does this mean they think you never had Aspergillus bronchitis?

No — not at all.

What it usually means is:

  • Aspergillus bronchitis was a reasonable and helpful way to understand your symptoms at the time

  • Over time, the balance has shifted

  • Aspergillus may now be less active or less central to how you are feeling

Medical understanding evolves, and long-term conditions often change their shape rather than disappear or suddenly become “wrong”.

Does discharge mean Aspergillus is no longer important?

Not exactly.

It usually means:

“We don’t think Aspergillus is the main thing driving your symptoms right now.”

It does not mean:

“Aspergillus will never matter again.”

Your specialists know that Aspergillus-related problems can:

  • Fluctuate

  • Become more relevant during periods of illness or change

  • Need revisiting later on

That possibility is built into discharge planning, even if it is not always said clearly.

Why does this still feel unsettling?

Because specialist care often feels like a safety net.

You may have felt:

  • Known and understood by the team

  • Reassured by specialist oversight

  • Protected by regular review

Thinking about discharge can feel like losing that protection — even when nothing is actually changing day to day.

That emotional response is completely understandable.

What discharge from a specialist service usually does mean

If discharge does happen, it usually means:

  • Your care continues with your GP or respiratory team

  • Your history does not disappear

  • You are not starting from scratch

  • Re-referral is expected if things change

Specialist teams rarely intend discharge to be permanent or final.

What about being re-referred if things worsen?

This is one of the most important points — and a reassuring one.

In most cases:

  • Re-referral is anticipated

  • Patients previously known to the service are often reviewed more quickly

  • You do not need to “prove” everything again

Discharge usually comes with an open door, even if that door is not labelled as such.

What helps patients feel safer at this stage

It is reasonable to want:

  • A clear explanation of why discharge is being discussed

  • Reassurance that this is about now, not forever

  • Clarity about what would prompt a return

  • Confidence that your GP knows your history

These are normal needs — not demands.

What you might gently ask your team

You could ask:

  • “If my symptoms change, would re-referral be straightforward?”

  • “What sort of changes should prompt a review?”

  • “Will my GP have clear guidance from you?”

  • “Is discharge something we can review over time?”

These questions often help turn uncertainty into reassurance.

Key things to hold onto

  • Discussion of discharge usually reflects stability, not dismissal

  • It does not mean your past diagnosis was wrong

  • It does not mean you are being left unsupported

  • Re-referral is part of good planning, not failure

  • Feeling unsure or vulnerable at this point is very common

In gentle terms

Talking about discharge usually means “you are doing well enough not to need us right now” — not “you never needed us” and not “you’re on your own”.

by GAtherton

Hyper-IgE syndrome

A patient-friendly guide (and why it matters if you have aspergillosis)

Hyper-IgE syndrome is a rare condition of the immune system. People with it have very high levels of an antibody called Immunoglobulin E (IgE), but their immune system does not work properly at fighting certain infections.

It is not the same as having lots of allergies, even though it can look very similar at first.

What is IgE, and why does it matter?

IgE is usually involved in allergies and asthma.

In Hyper-IgE syndrome:

  • IgE levels are extremely high (often many thousands)

  • But the immune system is unbalanced

  • This makes infections—especially in the lungs and skin—harder to control

So IgE is high, but protection is weak.

How might Hyper-IgE syndrome affect everyday life?

Not everyone has the same symptoms, but common features include:

Lung and chest problems

  • Repeated chest infections (often from a young age)

  • Ongoing cough, breathlessness and mucus

  • Lung damage such as bronchiectasis

  • Lung cavities that can later become infected by moulds such as Aspergillus

Skin and infection problems

  • Long-standing eczema or very sensitive skin

  • Recurrent skin infections or boils

  • Infections that keep coming back or take a long time to clear

Other clues (in some people)

  • Frequent infections in childhood

  • Bone or joint problems

  • Dental issues (for example baby teeth not falling out on time)

Why is this important for people with aspergillosis?

For many people, Aspergillus causes allergy or irritation.

In Hyper-IgE syndrome:

  • The immune system struggles to control moulds

  • Aspergillus can behave more like a true infection, not just an allergy

  • Lung damage can happen more easily and progress faster

This means doctors may need to:

  • Monitor lungs more closely

  • Treat fungal disease earlier and for longer

  • Be cautious with repeated or long-term steroid use

Specialist centres such as the National Aspergillosis Centre are often involved when aspergillosis and immune problems overlap.

Isn’t this just severe allergy or ABPA?

Hyper-IgE syndrome can look similar to:

  • Severe allergic asthma

  • Allergic Bronchopulmonary Aspergillosis (ABPA)

The key difference is that in Hyper-IgE syndrome:

  • The immune system itself is faulty

  • High IgE is part of a wider immune problem

  • Treating allergy alone may not be enough

Some people are treated for asthma or ABPA for years before this possibility is considered.

How is Hyper-IgE syndrome treated?

There is no single cure, but good treatment can make a big difference. The aim is to prevent infections, protect the lungs, and reduce symptoms.

1. Preventing infections (most important)

Because the immune system does not fight germs normally:

  • Some people take regular low-dose antibiotics

  • Others use antibiotics early and promptly when infections start

For people with aspergillosis:

  • Antifungal medicines may be needed

  • Monitoring is usually closer and longer-term

2. Protecting the lungs

Many people develop bronchiectasis or lung damage, so care often includes:

  • Airway clearance physiotherapy

  • Saline nebulisers to help clear mucus

  • Regular sputum tests

  • Early treatment of flare-ups

The goal is to stop the cycle of:

infection → inflammation → permanent lung damage

3. Managing inflammation and allergy (carefully)

People may also have asthma-like symptoms, eczema and multiple allergies.

  • Steroids can help symptoms, but long-term or frequent use can increase infection risk

  • Doctors usually try to keep steroid doses as low as possible

Biologic treatments (such as anti-IgE medicines):

  • May help some people

  • Do not fix the immune problem

  • Are considered on an individual basis, usually in specialist centres

4. Skin care

  • Regular moisturising

  • Prompt treatment of infected eczema

  • Good skin care helps reduce infection risk

How is Hyper-IgE syndrome diagnosed?

Diagnosis usually involves:

  • A detailed review of your medical history (often including childhood infections)

  • Blood tests of immune function

  • Referral to an immunology specialist

  • Sometimes genetic testing

Does having high IgE mean I definitely have this?

No.
Hyper-IgE syndrome is rare.

But it may be worth asking about if:

  • Your IgE has always been extremely high

  • You’ve had repeated infections for many years

  • You have bronchiectasis without a clear cause

  • Aspergillosis seems unusually persistent or severe

  • Standard asthma or allergy treatments don’t fully explain your symptoms

Key message

Very high IgE does not always mean “just allergy.”
In a small number of people, it reflects a deeper immune problem that changes how aspergillosis behaves and how it should be treated.

If your illness doesn’t quite fit the usual labels, it is reasonable to ask whether an immunology review would help.

by GAtherton